GlassScriptPhysician profile
James O Holt
NPI 1780962167
$5,030.60
in general payments reported to CMS, 2019-2025
23 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $393 · 2021: $288 · 2022: $225 · 2023: $897 · 2024: $1,028 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,250 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,250.16 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,162.69 | 2019-2025 | Idosetr, Idose Tr, Istent Trabecular Micro-Bypass System Model Is3 |
| Harrow Eye, LLC | $687.18 | 2024-2025 | Vevye |
| Alcon Vision LLC | $549.35 | 2019-2025 | Clareon, Argos |
| Tarsus Pharmaceuticals, INC. | $386.21 | 2024-2025 | Xdemvy |
| Rxsight INC | $321.76 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Shire North American Group INC | $218.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $174.74 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $169.49 | 2019-2025 | |
| Allergan, INC. | $153.08 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $150.55 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $144.45 | 2023-2025 | Infuse, Vyzulta, Miebo |
| Biotissue Holdings INC. | $134.12 | 2019-2025 | |
| Alcon Research LLC | $128.14 | 2019-2024 | Acrysof Iq Vivity |
| Rayner Intraocular Lenses Limited | $127.68 | 2024 | Omidria, Rayone Spheric, Rayone Emv |
| Quidel Corporation | $97.55 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $97.21 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $87.41 | 2019-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $69.01 | 2019-2021 | |
| Abbvie INC. | $46.95 | 2022-2024 | |
| Eyevance Pharmaceuticals LLC | $45.93 | 2019 | |
| Amgen INC. | $40.23 | 2024-2025 | Tepezza |
| Mallinckrodt Enterprises LLC | $19.99 | 2019 | |
| Sight Sciences, INC. | $18.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.